Trials / Unknown
UnknownNCT02916420
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
A Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 73 (estimated)
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess the efficacy and safety of pomalidomide in combination with low-dose dexamethasone in Chinese patients with relapsed and refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pomalidomide | 4mg/day, d1-d21, 28 days per cycle |
| DRUG | Dexamethasone | ≤70 years,40mg/day; \>70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2018-06-01
- Completion
- 2019-06-01
- First posted
- 2016-09-27
- Last updated
- 2016-11-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02916420. Inclusion in this directory is not an endorsement.